Navigation Links
Denver Spine Physicians Begin Enrollment in United States Stem Cell Therapy Study
Date:12/13/2011

GREENWOOD VILLAGE, Colo., Dec. 13, 2011 /PRNewswire-iReach/ -- DenverSpine today announced that it has enrolled its first patient in a nationwide FDA- cleared adult stem cell study testing novel treatment for chronic low back pain. The study will test the use of Mesenchymal Precursor Cells (MPCs) – adult stem cells derived from bone marrow that will be directly injected into the lumbar disc.  The minimally invasive procedure may offer an alternative to back surgery for eligible patients with chronic pain from degenerative discs.

An estimated 30 million people in the United States suffer from back pain. Degenerative disc disease is the most common cause of low-back pain, which develops with the gradual loss of a material called proteoglycan, which cushions the bones of the spine and enables normal motion.

Most patients with low-back pain respond to physical therapy and medications, but in advanced cases, artificial disc replacement or spinal fusion -- removal of the degenerated discs and the fusion of the bones of the spine -- is necessary. However, these surgeries often are not entirely effective.

J. Scott Bainbridge, M.D. is the lead researcher providing spinal injections for the study, and Gary Ghiselli, M.D. is the principal investigator. Both doctors agree on the critical need for a minimally invasive solution to a common, debilitating condition.

"The study is the first of its kind in the United States and we are very excited by the potential of these adult stem cells to provide a novel therapeutic approach," said Dr. Bainbridge.

Researchers will enroll approximately 100 study participants. About 10 – 20 participants will be enrolled at the Denver site and the rest at 11 other medical centers throughout the United States.  The trial is scheduled to last for three years.

DenverSpine is enrolling study participants suffering from moderate low-back pain for a minimum of six months and whose condition has not responded to other, conventional treatments.

Once enrolled, patients are randomly assigned to one of four treatment groups:

  • One group will receive a high dose of MPCs, plus hyaluronic acid, a substance that facilitates the localization and retention of the stem cells;
  • A second group will receive a lower dose of MPCs, plus the hyaluronic acid;
  • A third group will receive the hyaluronic acid alone;
  • A fourth group will receive only the saline solution.

Patients will receive a single injection of their assigned test agent directly into the center of the target discs within their spine and will be monitored for safety.  Patients will also be monitored using imaging to identify any changes in their disease condition or disease progression. Use of pain medications, self-reports of pain, subsequent surgical interventions and assessments of disability, quality of life, productivity and activity will be evaluated. Repair of the disc and reduction of chronic back pain will be assessed in each patient. 

Promising results have been observed in prior research using animal models when stem cells were investigated for the repair of damaged spine discs.The cells were well tolerated in these study animals.

This study is sponsored by Mesoblast Limited,a world leader in the development of biologic products for the broad field of regenerative medicine.  Mesoblast has the worldwide exclusive rights to a series of patents and technologies developed over more than 10 years relating to the identification, extraction, culture and uses of adult Mesenchymal Precursor Cells (MPCs).  The MPCs are derived from young adult donors' bone marrow and are immune tolerant.

For more information, go to www.denverspine.com.

For additional information on the clinical trial, please see the listing on www.clinicaltrials.gov study identifier number NCT01290367

Media Contact: Jami Henriksen, DenverSpine, 303-783-1300 ext 158, jhenriksen@denverspine.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE DenverSpine
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cheyenne Regional Medical Center Announces New Air Ambulance Service Partnership with HealthONEs AirLife Denver
2. Colorado Association of School Nurses Unites Denver Community to Combat Low Meningitis Vaccination Rates Among Preteens and Teens
3. Denver School Nurses Unite Community in the Fight against Meningitis, a Potentially Deadly Disease
4. Denver Zoo Orangutan Breathes Easier With eFlow Technology From PARI
5. Invision Sally Jobe Introduces New Breast Cancer Screening Technology to Denver
6. Denver-Ft. Collins Ophthalmologist First in Colorado to Implant nanoFLEX Lens
7. American Lung Association in Colorados Faces of Influenza Initiative Rolls Up its Sleeves to Kick Off Flu Season in Denver
8. CSC Announces Billing Contract with Denver Endocrinology Diabetes and Metabolism
9. SpineMark Partners With Regional Spine Leaders to Launch Its First Multisite Spine Research Organizations in Los Angeles, Denver
10. RSB Spine, LLC, Announces European Patent Allowance
11. Thompson MIS Wins a Best New Technology in Spine Care 2011 Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today provided an update ... Puerto Rico , where the company manufactures ... Following a comprehensive onsite assessment, the ... temporary loss of power and minimal water damage due ... have resumed, and the company expects to return to ...
(Date:10/7/2017)... Oct. 6, 2017   Provista, a proven ... $100 billion in purchasing power, today announced a new ... The Newsroom is the online home for ... infographics, expert bios, news releases, slideshows and events. ... a wealth of resources at their fingertips, viewers can ...
(Date:10/4/2017)... -- According to the Centers for Disease Control and Prevention (CDC), influenza ... Care is helping communities across Massachusetts , ... no-cost* flu shots through the end of the month. *Some ... ... flu shot is by the end of October, according to the Centers ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ... Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, ... guideline updates for the primary prevention of cardiovascular diseases during the 15th ...
(Date:10/13/2017)... NY (PRWEB) , ... October 13, 2017 , ... Ellevate ... people in business to advocate for action towards gender equality at their inaugural Summit ... from around the globe, and reached a social audience of over 3 million. To ...
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a ... “The Journey: From the Mountains to the Mission Field” is the creation of published ... all ages and currently teaches a class of ladies at her church, which she ...
(Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
(Date:10/12/2017)... ... 12, 2017 , ... Dr. Parsa Mohebi, the Los Angeles ... to the newly revamped Cosmetic Town journal section, featuring articles written ... known as Follicular Unit Extraction (FUE). , Dr. Mohebi says “I ...
Breaking Medicine News(10 mins):